*Opdivo ([[nivolumab]]) is a [[PD-1|programmed death receptor]] blocking antibody used for the treatment of unresectable or metastatic melanoma and metastatic squamous [[non-small-cell lung carcinoma]]. In contrast to traditional chemotherapies and targeted anti-cancer therapies, which exert their effects by direct cytotoxic or tumor growth inhibition, nivolumab acts by inducing the immune system to attack the tumor.<ref>{{cite journal |vauthors=Johnson DB, Peng C, Sosman JA |title=Nivolumab in melanoma: latest evidence and clinical potential |journal=Ther Adv Med Oncol |volume=7 |issue=2 |pages=97â€“106 |year=2015 |pmid=25755682 |pmc=4346215 |doi=10.1177/1758834014567469 |url=}}</ref>
